Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nerve Gas Agent Pyridostigmine Is First Approval Under Animal Efficacy Rule

Executive Summary

FDA's approval of pyridostigmine bromide as a pretreatment against Soman nerve gas is the first under the agency's animal efficacy rule

You may also be interested in...



Levaquin Approval For Plague Carries Just One Postmarketing Requirement

Study requirement for J&J’s antibiotic is less onerous than the studies that were imposed for the two other products approved under the Animal Rule.

Animal Rule Studies Should Be As Well-Designed As Human Clinical Trials, Panel Says

FDA's Anti-Infective Drugs Advisory Committee unanimously said ciprofloxacin and Ortho-McNeil-Janssen Pharmaceuticals Inc.’s Levaquin (levofloxacin) had proven their efficacy for pneumonic plague in studies in African Green Monkeys, but the panel may be less willing to overlook study design flaws in less life-threatening conditions.

FDA Animal Efficacy Rule Drops Superiority Requirement For New Agents

FDA's final rule allowing drug approvals based on animal efficacy studies will permit more than one drug to be approved for an indication without a clear demonstration of superiority over existing products

UsernamePublicRestriction

Register

PS041254

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel